Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MDH2 | P40926 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25748258 | 0.92 | PTPN1 (0.39) | HTR1DMEN1KMT2APTPN1ALDH1A1 | |
| SCHEMBL25748242 | 0.91 | HTR2A (0.39) | HTR1DPTPN1ALDH1A1HPGDMDH2 | |
| SCHEMBL25426159 | 0.87 | PTPN1 (0.38) | HTR1DMEN1KMT2APTPN1ALDH1A1 | |
| SCHEMBL31077657 | 0.84 | PTPN1 (0.38) | MEN1KMT2APTPN1ALDH1A1HPGD | |
| SCHEMBL25748246 | 0.84 | PTPN1 (0.38) | HTR1DMEN1KMT2APTPN1ALDH1A1 | |
| SCHEMBL25748215 | 0.83 | PTPN1 (0.42) | MEN1KMT2APTPN1ALDH1A1HPGD | |
| SCHEMBL30483756 | 0.82 | APP (0.42) | MEN1KMT2APTPN1SMN1; SMN2HTR2A | |
| SCHEMBL1163488 | 0.77 | HPGD (0.39) | HTR1DMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL25748229 | 0.75 | SLC6A4 (0.39) | HTR1DMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL25438497 | 0.74 | ALDH1A1 (0.39) | HTR1DMEN1KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101038-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-03-27 | — | — | US | disclosed |
| CN-118715204-A | Compounds of formula (I) | 普赛洛私人有限公司 | 2024-09-27 | — | — | CN | disclosed |
| WO-2023115166-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101038-A1 | COMPOUNDS | NLN, SLC18A2, PYGB | HTR1D 344/4885MEN1 1401/4885KMT2A 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.